All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.

The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy


Now you can personalise
your AML Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more

The AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
You're logged in! Click here any time to manage your account or log out.
You're logged in! Click here any time to manage your account or log out.

What time is the right time for transplantation?

Aug 3, 2023
Learning objective: After reading this article, learners will be able to cite a development in the use of stem cell transplantation in the treatment of AML.

On June 29, 2023, the AML Hub hosted a discussion on “What time is the right time for transplantation?”, chaired by Selina Luger, with contributions from Steering Committee members Gert Ossenkoppele, Jeffrey Lancet, Yasushi Miyazaki, Eduardo Rego, Roland Walter, and Jorge Sierra.

What time is the right time for transplantation?


Using a case of a patient with primary refractory acute myeloid leukemia (AML), Luger discusses the options of immediate allogeneic stem cell transplantation or after achievement of remission with salvage chemotherapy. Luger then highlights the phase III ASAP trial (previously covered by the AML Hub), the Pre-MEASURE trial (previously covered by the AML Hub), and also describes a study that found allogeneic stem cell transplantation outcomes were associated with high-sensitivity detection of FLT3-internal tandem duplication measurable residual disease.

The group discusses the results of these studies, including the differences in patient populations, optimal timing of transplantation, the impact of pretransplant measurable residual disease, and whether or not salvage chemotherapy is beneficial for these patients. They also raise the importance of identifying donors for potential transplantation as early as possible.


Subscribe to get the best content related to AML delivered to your inbox